The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3671-3677

  Holmes, Valerie A ^a   Young, Ian S ^a   Patterson, Christopher C ^a   Maresh, Michael J A ^b   Pearson, Donald W M ^c   Walker, James D ^d   McCance, David R ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d ST JOHN'S HOSPITAL   (United Kingdom)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTAL GROWTH FACTOR; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DULT; GESTATIONAL AGE; INSULIN DEPENDENT DIABETES MELLITUS; MATERNAL PLASMA; PATHOGENESIS; PREECLAMPSIA; PREGNANT WOMAN; PROGNOSIS; RISK FACTOR; SECOND TRIMESTER PREGNANCY; ADULT; AREA UNDER THE CURVE; BLOOD; CONTROLLED STUDY; FEMALE; HUMAN; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84891849658     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0944     Document Type: Article

References (24)

1. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV
2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J ObstetGynecol 2000;183:S1-S22
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33: 130-137
4. Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004;27:2819-2823
5. Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, populationbased study. Diabetes Care 2009;32:2005-2009
6. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007 (2): CD004659
7. Meis PJ, Goldenberg RL, Mercer BM, et al.; Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. The preterm prediction study: risk factors for indicated preterm births. Am J Obstet Gynecol 1998; 178:562-567
8. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33-46
9. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658
10. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-683
11. McKeeman GC, Ardill JES, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191:1240-1246
12. Levine RJ, Lam C, Qian C, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005
13. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23
14. Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199:268.e1-268.e9
15. Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of pre-eclampsia in high risk women. AmJ Obstet Gynecol 2007;197:244e1-244e8
16. Cohen A, Lim KH, Lee Y, Rana S, Karumanchi SA, Brown F. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care 2007;30:375-377
17. Yu Y, Jenkins AJ, Nankervis AJ, et al. Antiangiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 2009; 52:160-168
18. Powers RW, Jeyabalan A, Clifton RG, et al.; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 2010;5:e13263
19. McCance DR, Holmes VA, Maresh MJ, et al.; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 2010;376:259-266
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROCcurve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212
21. Holmes VA, Young IS, Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011;34:1683-1688
22. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22:1021-1038
23. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740-746
24. Hlatky MA, Greenland P, Arnett DK, et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association [corrected in Circulation 2009; 119;e606]. Circulation 2009;119:2408-2416